Breaking News
Investing Pro 0
Final hours: unlock premium data with Claim 60% OFF

Bausch + Lomb's Saunders doesn't expect more big deals in the near term

Published Aug 02, 2023 07:01 Updated Aug 02, 2023 14:38
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Bausch & Lomb eye care and contact lens related products are seen for sale in a pharmacy in Washington, U.S., May 6, 2022. REUTERS/Leah Millis/File Photo
 
AGN
0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
-0.67%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LCO
+2.16%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BHC
+2.06%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ABBV
+0.84%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Elissa Welle

(Reuters) -Eye care firm Bausch + Lomb does not expect to do another big deal for around a year after it completes its $1.75 billion deal for dry eye drug Xiidra, recently rehired chief executive Brent Saunders said on Wednesday.

Noted dealmaker Saunders has already announced two acquisitions since joining the company in March: the deal to buy Xiidra from Novartis in June and a $106.5 million deal for Johnson & Johnson (NYSE:JNJ)'s eye and contact lens drops brand Blink.

"We need to close this one by the end of the year, we need to integrate it into the company and then we need to digest, de-lever from a balance sheet perspective," Saunders said in an interview, adding that the company will look for smaller opportunities over that time frame.

Bausch + Lomb also posted modestly better than expected second-quarter earnings on Wednesday, reporting revenue of $1.04 billion in the quarter, up from $941 million a year ago. Analysts, on average, expected revenue of $963 million for the quarter, according to Refinitiv data.

Excluding one-time items, B+L said it earned $65 million, or 18 cents per share, down from $103 million or 29 cents per share last year, as the company's expenses rose. Still, the earnings beat analysts' expectations by 3 cents a share.

Saunders previously helmed and built up Botox maker Allergan (NYSE:AGN) before it was acquired by AbbVie (NYSE:ABBV) for $63 billion in 2020.

This is his second stint at Bausch + Lomb, which makes contact lenses, surgical devices, prescription drugs and generic eye products. In 2013, Saunders oversaw B+L's acquisition of Valeant Pharmaceutical, now Bausch Health (TSX:BHC) Companies.

Bausch Health still owns most of B+L’s shares and has said it intends to fully spin the company off. Some Bausch Health investors are trying to block the spin-off.

"They have not put out a timeline for the remaining spin, but I'm confident that that will happen in due course," Saunders said.

Bausch + Lomb's Saunders doesn't expect more big deals in the near term
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email